ClinicalTrials.gg
Active, not recruitingNCT07126756TG-LASIK vs SMUpdated Aug 17, 2025

LASIK iDesign vs SMILE

An interventional study of STAR S4 IR Excimer Laser System and VisuMax 400 Surgical Laser in Myopia and Astigmatism, sponsored by 59th Medical Wing. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by 59th Medical Wing · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as active, not recruiting.
  • Registered 1 year 2 months after the study started (first participant enrolled Jun 2024, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 342 studies in Myopia with a site in United States — 27 open to participants now, 44 under way, 3 of them phase 3. Myopia · United States.

Planned enrollment
178th of 294
57 · median 68
Started
2024
with 19 others
No phase
243 of 342
16 open now
Primary completion
2025-12
later than 5 of 43 live
Registered
319th of 342
by date

Among the 342 studies in Myopia with a site in United States, this one is the 178th largest by planned enrollment of the 294 interventional ones that give a count, is one of 20 that started in 2024, is one of 243 with no phase, reaches primary completion later than 5 of the 43 other live ones, and was the 319th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

27 of the 342 studies in Myopia with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 21 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Myopia with a site in United States, or all of them as a file.
02

Study summary

The study will compare the 6-month visual outcomes (i.e., visual acuity, contract sensitivity, higher order aberrations), quality of vision (i.e., double vision, glare, starburst, halos, etc.) and dry eye symptoms of patients undergoing contralateral LASIK using iDesign and SMILE surgery.

Read the detailed description

Both SMILE and LASIK treatments are FDA-approved and are both performed routinely as standard of care surgery in the US Military. However, there is limited literature comparing quality of vision after LASIK using iDesign and SMILE refractive surgery. Our objective is to study the 6-month visual outcomes (high and 5% low contrast visual acuity, refractive error, higher order aberrations) and subject reported quality of vision (i.e., double vision, glare, starburst, halos, etc.) and dry eye symptoms using the PROWL and SPEED questionnaires following contralateral LASIK using iDesign and SMILE surgery. This is a prospective randomized contralateral study, including 57 subjects. Once consented to participate in the study, subjects will have a comprehensive ocular examination to determine eligibility to undergo simultaneous SMILE surgery in one eye and LASIK using iDesign on the contralateral eye to correct myopia. Surgical treatment will be randomized so there is a 50% chance to receive SMILE on the right eye and LASIK on the contralateral eye. Subjects will receive standard of care topical ophthalmic antibiotic and steroid drops. Visual outcomes and patient self-reported symptoms will be assessed at day 1, week 2, month 1, month 3, and month 6.

03

Conditions studied

  • Myopia
  • Astigmatism
04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Nearsightedness (myopia) between -2.00 diopters and -8.00 diopters
  2. Have similar levels of nearsightedness in each eye (2D or less difference between eyes)
  3. Less than or equal to 3.00 diopters of astigmatism
  4. Total spherical equivalent (SE) of no more than -8.0 D
  5. Tricare Prime/Select Beneficiary (military health insurance)
  6. Residing within 60 miles radius from Lackland AFB

Exclusion criteria

Exclusion Criteria:

  1. Subjects with corneal abnormal findings including signs of keratoconus, keratoconus suspect, abnormal corneal topography, epithelial basement membrane disease, pellucid marginal degeneration, corneal degenerations, progressive and unstable myopia, irregular or unstable corneal mires on central keratometry images, and volunteers whose corneal thickness would cause anticipated treatment would violate the posterior 250 microns (um) of corneal stroma from the corneal endothelium.
  2. Subjects with active collagen vascular, connective tissue, or immunodeficiency diseases
  3. Pregnant or nursing females (pregnancy test will be performed on females subjects of )
  4. Systemic disease likely to affect wound healing, such as uncontrolled diabetes and severe atopy
  5. Any ocular disease such as advanced/uncontrolled glaucoma, severe dry eye, active eye infection or inflammation, recent herpes eye infection or problems resulting from past infection.
  6. 0.25 or 0.50 of manifest astigmatism in the eye randomized to SMILE
  7. Taking the medication Isotretinoin (Accutane) or antimetabolites for any medical condition.
  8. Potential candidate who cannot provide will not be allowed to participate.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (estimated)

Study arms

  • Active comparator
    LASIK using iDesign

    LASIK guided by iDesign

    Device: STAR S4 IR Excimer Laser System

  • Experimental
    SMILE

    SMILE Refractive Surgery

    Device: VisuMax 400 Surgical Laser

Interventions

  • DeviceSTAR S4 IR Excimer Laser System

    LASIK with iDesign

    Also known as: iDesign Refractive Studio

  • DeviceVisuMax 400 Surgical Laser

    small incision lenticule extraction technique

06

What researchers measure

Primary outcomes

  1. Percentage of Eyes With Uncorrected Visual Acuity of 20/16 or Better at 6-month Post-Op

    Post-operative uncorrected visual acuity of 20/16 or better measure using the ETDRS chart reported as percentage of subjects; unit = percentage eyes with Uncorrected Visual Acuity

    Time frame: 6-month Post-Op

Secondary outcomes

  1. Difference in High Contrast Visual Acuity at 6-month Post-Op

    Mean uncorrected high contrast visual acuity measure using the ETDRS chart measure at 6-month Post-Op; unit = LogMAR

    Time frame: 6-month Post-Op

  2. Difference in residual Refractive Error at 6-month Post-Op

    Residual mean refractive error measure with phoropter at 6-month Post-Op; unit = Diopters (D)

    Time frame: 6-month Post-Op

  3. Difference in Low Contrast Visual Acuity at 6-month Post-Op

    Mean uncorrected low contrast visual acuity measure using the 5% ETDRS chart measure at 6-month Post-Op; unit = LogMAR

    Time frame: 6-month Post-Op

  4. Difference in residual Higher Order Aberrations at 6-month Post-Op

    Mean Higher Order Aberrations measure by iDesign 2.0 Refractive Studio at 6-month Post-Op; unit = root mean square

    Time frame: 6-month Post-Op

  5. Difference in overall satisfaction questionnaire score at 6-month Post-Op

    Mean Subject Satisfaction Score with the surgery outcome using the Patient-Reported Outcomes with LASIK Symptoms and Satisfaction (PROWL-SS) Questionnaire at 6-month Post-Op. The score ranges from 1 (completely satisfied) to 6 (completely dissatisfied). Lower value indicates higher satisfaction.

    Time frame: 6-month Post-Op

  6. Difference in overall Dry Eye questionnaire score at 6-month Post-Op

    Mean Standard Patient Evaluation of Eye Dryness (SPEED) Questionnaire score at 6-month Post-Op. Possible dry eye symptoms score ranges from 0 (never) to 3 (Constant). Higher value indicates worse dry eye symptoms.

    Time frame: 6-month Post-Op

07

Study locations

1 site
  • Joint Warfighter Refractive Surgery Center, Wilford Hall Ambulatory Surgical Center
    Lackland Air Force Base, Texas 78009, United States
08

References and documents

Publications

  • Ma KK, Manche EE. Patient-reported quality of vision in a prospective randomized contralateral-eye trial comparing LASIK and small-incision lenticule extraction. J Cataract Refract Surg. 2023 Apr 1;49(4):348-353. doi: 10.1097/j.jcrs.0000000000001127. PubMed 36539217 ↗
  • Bharti S, Bains HS. Active cyclotorsion error correction during LASIK for myopia and myopic astigmatism with the NIDEK EC-5000 CX III laser. J Refract Surg. 2007 Nov;23(9 Suppl):S1041-5. doi: 10.3928/1081-597X-20071102-11. PubMed 18047004 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2025, 18 months after the start.

Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 18 months is below that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Aug 17, 2025
StartActual
Jun 10, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jan 31, 2026
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07126756
Lead sponsor
59th Medical Wing
Collaborators
United States Army Aeromedical Research Laboratory
Responsible party
Sponsor
First posted
Aug 17, 2025
Start date
Jun 10, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Jan 31, 2026 (estimated)
Last update
Aug 17, 2025

Study contacts

Charisma B Evangelista, MD
principal investigator · Joint Warfighter Refractive Surgery Center, Wilford Hall Ambulatory Surgical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion